By comparison, semaglutide plateaued around 14.9% and tirzepatide around 22.5% during active treatment in the data ASMBS reviewed, which will be much lower (maybe even close to zero) whenever we are able to get 10 year data on these patients, as few will be able to continue treatment for 10 years
GLP-1 receptor agonists are not controlled substances, so DEA remote-prescribing rules do not apply to them
10.1016/0024-3205(86)90540-0 Hoshi T, Heinemann S: Regulation of cell function by methionine oxidation and reduction
The evidence is clear: while GLP-1s can help kick-start change, behavior change is the key to sustained success
This association was more pronounced in individuals who consistently used SSRIs
Rabizadeh S, Nakhjavani M, Esteghamati A (2019) Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review